

Index

- acceptability, of screening program, 422–423
- A549 cells, 447
- acetylcholine, 6. *See also* nicotinic acetylcholine receptors
- acetyl-11-keto-beta-boswellic acid (AKBA), 448
- acinar adenocarcinoma, 123*t*, 125–127, 132*t*
- active breathing control (ABC), 248
- adaptive radiotherapy, 250
- adaptogens, 451
- Adathoda vasica*, 444
- adenocarcinoma, 121–137
 - classification of, 122–124
 - bronchioalveolar (*see* bronchioalveolar carcinoma (BAC))
 - clear cell, 127
 - fetal, 128
 - invasive, 125–127
 - mucinous, 127
 - mucinous cystadenocarcinoma, 127
 - papillary, 127
 - sclerosing, 128
 - signet ring, 127
 - definition of, 122
 - diagnostic molecular studies, 130–133
 - fluorescence in situ hybridization, 133
 - gene expression profiling, 133
 - immunohistochemistry, 130–133
 - experimental models of, 136–137
 - grading criteria, 125
 - histopathological changes in, 86*f*
 - macroscopic patterns of, 128
 - molecular pathogenesis of, 91*f*, 135–136
 - origins of, 129–130
 - pathogenesis of, 90–92
 - pathological features of, 123*t*
 - and peripheral airway, 121–122
 - precursor lesions, 86, 422
 - preneoplastic lesions and, 107
 - tissue biomarkers in, 131
- adenomatosis polyposis coli (APC), 68*t*
- adenosquamous adenocarcinoma, 123*t*
- adjuvant chemotherapy, 221–230
 - carboplatin *vs.* cisplatin, 228–229
 - clinical trials, 221–227
 - Adjuvant Lung Project Italy, 224–225
 - ANITA 01, 226–227
 - Big Lung Trial, 225–226
 - Cancer and Leukemia Group B trial, 227
 - International Adjuvant Lung Cancer Trial, 225
 - Italian stage IB study, 223
 - Japanese Oncology Group Trial 9304, 223–224
 - National Cancer Institute of Canada Clinical Trials Group JBR.10, 226
 - North American Intergroup Trial INT0115, 222–223
 - pooled analysis of, 227–228
 - customized, 229–230
 - doublets *vs.* triplets, 228
 - overview of, 221–222
 - and stages of lung cancer, 228
 - vs.* neoadjuvant setting, 229
 - Adjuvant Lung Project Italy (ALPI), 224–225
- adolescent smokers, 5
 - initiation to smoking, 5–6
 - nicotine dependence in, 7
- Ad-p53 adenoviral vector, 412–416
- ADRB2 gene, 68*t*
- AE-941, 378
- Affymetrix 70-gene assay, 161
- Affymetrix Human Exon chip, 155
- African-Americans, susceptibility to smoking, 426
- aggrecan, 45
- AKT gene, 63*t*
- Alagille syndrome, 71*t*
- aldehyde dehydrogenase, 68*t*
- ALDH1A3G gene, 68*t*
- allogeneic tumors, 340
- all-trans-retinoic acid (ATRA), 386
- Alpha-Tocopherol and Beta-Carotene Cancer Prevention Study Group (ATBC), 388
- altered negative selection, 336
- alveolar cells, 122
- alveolar septum, 121–122
- aminotransferase (AST), 377
- aneuploidy, 64–65
- angiogenesis, 369
 - inhibition of, 370
 - in lung cancer, 369
 - regulators of, 369–370
- angiogenic squamous dysplasia (ASD), 86, 111
- angiography, 203
- anterior mediastinoscopy, 172–173
- antiactivator protein-1 (anti-AP-1), 447
- antiangiogenic agents, 369–380. *see also* chemotherapeutic agents
 - clinical trials of, 370–372
 - in combination with targeted therapies, 376
 - as first-line therapy, 372–375
 - as monotherapy, 375–376
 - in neoadjuvant and adjuvant settings, 377–378
 - as second-line therapy, 375
- antiapoptotic genes, 412
- antibodies, 62
 - as antiangiogenic agents, 370–371
 - in molecular profiling, 157–158
 - tumor-associated, 435
 - and tumor cell vaccines, 340
- antibody microarrays, 158
- antifolate, 324–325
- antigen presenting cells (APCs), 335
- antihistamine agents, 317
- anti-inflammatory genes, 45
- antimetabolites, 320–321
- aorta, 172, 204, 207–209, 213–215
- APE1 repair gene, 40
- apigenin, 443
- apoptosis, 43–44
 - genetic polymorphisms, 43–44
 - phenotypic assays, 44
 - role of p53 gene in, 401–402
 - of tumor cell, 446
- aprinocarsen, 326
- argon plasma coagulation, 117
- arsenic, 34
- asbestos, 34
- ASD lesions, 90
- ashwagandha, 451
- aspirin, 447
- ATM repair gene, 40
- atypia, 103–105

- atypical adenomatous hyperplasia (AAH), 106–107
 detection of, 422
 origins of, 129–130
 pathological features of, 123*t*
- autofluorescence bronchoscopy, 100–101
 in chest computed tomography
 screening, 433
 clinical trials, 101–103
 equipment, 100–101
 indications for, 103–106
 bronchial intraepithelial neoplasia, 106
 early central carcinoma, 105
 severe sputum atypia, 103–105
 suspected/early/previous lung cancer, 105
 poor specificity of, 434
- autologous tumors, 340
- automated quantitative cytometry (AQC), 434
- axitinib, 327*t*, 376–377
- AZD2171, 374–375
- Bach's model, 48
- Bacille-Calmette-Guerin (BCG) vaccine, 343–344
- base-excision repair (BER), 38
- basement membrane, 104*f*
- basic fibroblast growth factor (bFGF), 369
- basonuclin-1, 63*t*, 68*t*
- BCL2-interacting killer (BIK), 68*t*
- BEACON study, 378
- behavioral counseling, 10
- belagenpumatucel-L, 344
- Benadryl, 317
- benzopyrene, 63, 443, 451–452
- benzopyrene diol-epoxide (BPDE), 38
- berberine, 447
- Berberis aristata*, 447
- BER repair gene, 39
- beta-carotene, 20, 35
- Beta-Carotene and Retinol Efficacy Trial (CARET), 35, 47–48, 389
- beta-elemene, 446
- beta-endorphin, 6
- betaig-h3 gene, 68*t*
- betel nuts, 387
- bevacizumab, 372–374. *see also*
 antiangiogenic agents
 in combination therapy, 315
 neoadjuvant vs. adjuvant setting, 377–378
 in small cell lung cancer (SCLC)
 treatment, 379–380
 with targeted therapies, 375
- bexarotene, 326, 393–396
- B16F-10 melanoma cells, 451
- bidis, burned tobacco, 5
- Big Lung Trial, 225–226, 240
- bilobectomy, 113
- Bimodality Lung Oncology Team Trial (BLOT), 236–237
- bioflavonoids, 444
- biological agents, 325–327
 glutathione-S-transferase, 327
 histone deacetylase enzymes, 327
 matrix metalloproteinases, 326–327
 mTOR gene, 327
 protein kinase C, 326
 proteasome, 326
 Raf kinase, 326
 Ras oncogene, 327
 retinoids, 326
 Src kinase, 327
- biological effective dose (BED), 266
- biomarkers, 359
- biophotonic imaging, 99–100
- bischloromethyl ether, 34
- black pepper, 443
- bleomycin, 40
- blood, detection of DNA abnormalities in, 435–436
- BLU gene, 88
- bortezomib, 400–407
 anticancer activity of, 400–402
 in bronchioalveolar carcinoma
 treatment, 149
 with chemotherapeutic agents, 326
 docetaxel, 404–405
 erlotinib, 405–406
 gemcitabine, 404
 platinum-based doublets, 406
 sequence specificity, 402
 clinical trials of, 150*t*, 403–406
 pharmacology of, 402–403
 single-agent studies, 403–404
 in small cell lung cancer (SCLC)
 treatment, 406–407
- Boswellia serrata*, 448
- boswellic acids, 448
- brachytherapy, 117, 423
- BRAF gene, 63*t*
- Bragg peak, 272, 273
- BrainLab, 251
- breathing, monitoring of, 248
- British Columbia Cancer Research Centre, 100
- bronchioalveolar carcinoma (BAC), 124–125. *see also* adenocarcinoma
 cytology of, 128–129
 definition of, 124–125, 144
 detection of, 128
 diagnostic molecular studies, 130–133
 immunohistochemical markers for, 132*t*
 molecular target agents in, 149
 pathological features of, 123*t*
 spread patterns, 128
 diffuse, 128
 nodules, 128
 pneumonic form, 128
 subtypes of, 144
 survival rates for, 423
- treatment of, 144–150
 chemotherapy, 146–147
 curative surgery, 145
 EGFR-TKI, 147–149
 palliative surgery, 145
 transplantation, 145–146
 treatment response predictors, 133–135
- bronchoalveolar lavage (BAL), 436
- bupropion, 15
- butylated hydroxyanisole (BHA), 448
- cadherin 1 (E-cadherin), 68*t*, 132
- cadherin 13 (H-cadherin), 69*t*
- calcitonin, 68*t*
- California-Pittsburgh Cancer Consortium, 149
- calponin homology, 71*t*
- calretinin, 131*t*
- Camellia sinensis*, 446–447
- Camptotheca acuminata*, 322
- cancer, 1–3
 deaths from, 20
 genetics of, 61–62
 hallmarks of, 66
 immunoeediting, 334–335
 immunosurveillance, 334
- Cancer and Leukemia Group B trial, 227, 2854
- cancer immunotherapy, 337–344
 dendritic cell vaccines, 338–339
 gene delivery vaccines, 343–344
 immune adjuvant vaccines, 343–344
 modified tumor cell vaccines, 340–341
 peptide vaccines, 341–343
 protein vaccines, 341–343
- cancer patients
 families of, 21–25
 screening program for, 425–426
 smoking among, 3–4
 statistics, 271
- carboplatin, 228–229
 in adjuvant setting, 223*t*
 in combination therapy with
 bexarotene, 395
 bortezomib, 150*t*, 406
 docetaxel, 319
 irinotecan, 322
 paclitaxel, 227–228, 237–238
 vinorelbine, 324
 dosing regimens, 316*t*
 vs. cisplatin, 228–229, 315
- carcinoembryonic antigen, 131*t*
- carcinogen metabolizing enzymes, 36–38
 CYP1A1, 36
 CYP2A6, 36
 CYP2A13, 36
 CYP1B1, 36
 CYP2C9, 37
 CYP2D6, 37
 CYP2E1, 37
 epoxide hydroxylase 1 (EPHX1), 38
 glutathione peroxidase I (GPX1), 38

- GST family, 37–38
 myeloperoxidase (MPO), 37
 N-acyltransferases (NATs), 38
 NAD(P)H:quinone oxidoreductase 1 (NQO1), 38
 sulfotransferase (SULT), 38
 carcinoid tumors, 87, 422
 carcinoma in situ (CIS), 113–117. *see also* adenocarcinoma
 depth of invasion, 114–115
 detection of preneoplastic lesions in, 104*f*, 106
 eligibility for endobronchial therapy, 114
 endobronchial therapies, 114–117
 brachytherapy, 117
 cryotherapy, 117
 electrocautery, 116–117
 photodynamic therapy, 115–116
 lymph node assessment, 114–115
 preclinical phase, 422
 surface characteristics of, 114
 treatment of, 113–114
 cardiopulmonary bypass (CPB), 213–215
 cardiovascular diseases, 2*t*, 9
 CARET model, 47–48
 carinal resections, 204–208
 left carinal pneumonectomy, 206–208
 right carinal pneumonectomy, 205–206
 without lobar resection, 206
 without pulmonary resection, 204–205
 carotenoids, 34–35, 391–392
 casein, 45
 caspase 8, 68*t*
 CASP9 gene, 43
 casuarinin, 442*t*, 450
 catechins, 446–447
 cathepsin B, 318
 cathepsin Z, 69*t*
 caveolin 1, 68*t*
 CCI-779, 327
 CCND1 gene, 43
 CC10 protein, 121
 CD25 cells, 336–337
 CDK4, 75–76
 CD24 molecule, 68*t*
 CD4 T cells, 336–337, 343
 CD8 T cells, 343
 CDX2, 131*t*
 celecoxib, 337
 cell cycle control, 42–43
 genetic polymorphisms, 42–43
 phenotypic assays, 43
 cell-mediated immune (CMI) responses, 335
 Center for Inherited Disease Research (CIDR), 27
 ceroids, 100
 cervical mediastinoscopy, 170–173
 complications, 171–172
 extended, 172–173
 history of, 170
 indications for, 170–171
 procedure, 171
 results, 171
 video-assisted, 173
 Chantix, 15
 charge-coupled devices (CCDs), 101
 chemo-naïve patients, 230, 315, 318, 319–327
 chemoprevention agents, natural, 441–452
 adaptogen mechanism, 451–452
 ginsenosides, 451–452
 whitanolides, 451
 anti-inflammatory, 444–452
 berberine, 447
 beta-elemene, 446
 boswellic acids, 448
 casuarinin, 450
 catechins, 446–447
 curcumin, 445
 curcuminoids, 445–446
 daidzein, 449
 E-guggulsterone, 448–449
 ferulates, 448–449
 genistein, 449
 gingerol, 446
 glabridin, 449–450
 glycyrrhetic acids, 449–450
 isoliquritigenin, 447
 myo-inositol, 448
 zerumbone, 446
 Z-guggulsterone, 448–449
 cytochrome P450 enzyme modifiers, 442–444
 E-guggulsterone, 444
 hypericin, 443
 indole-3-carbinol, 443
 piperine, 443
 quercetin, 444
 resveratrol, 442–443
 Z-guggulsterone, 444
 enhancement of selenoproteins, 450
 chemotherapeutic agents, 315–327
 antimetabolites, 320–321
 multitargeted antifolate, 324–325
 taxanes, 317–320
 docetaxel, 319–320
 paclitaxel, 317–318
 topoisomerase inhibitors, 321–323
 vinca alkaloids, 323–324
 chemotherapy, 221–230
 adjuvant, 221–230
 cisplatin-based, 286, 288, 289, 291, 292, 305
 and gene replacement, 413–415
 molecular profiling in, 163
 and proteasome inhibition, 402
 with radiation therapy, 283–294
 concurrent, 286–288
 concurrent followed by resection, 292–294
 induction chemotherapy before radiotherapy, 284–286
 sequential vs. concurrent, 288–292
 in treatment of microscopic/nodal disease, 298–299
 Chemotherapy in Early Stages in NSCLC Trial, 241
 chest computed tomography, 428–433
 chest radiography, 426–428
 chest wall resections, 194–197
 chewing tobacco, 5
 chippers, 6
 chromium, 34
 chromosomal instability, 64–65
 chronic obstructive pulmonary diseases (COPD), 93, 335, 426, 444
 cigarettes, 4–5
 cigarette smoking. *see* smoking
 cigars, 5
 CI-1033 inhibitor, 361
 cisplatin, 228–229. *see also* chemotherapeutic agents
 cisplatin-based chemotherapy, 286, 288, 289, 291, 292, 305
 clinical trials, 221–228
 in combination therapy with
 bexarotene, 395
 gemcitabine, 321
 irinotecan, 322
 pemetrexed, 324
 vinorelbine, 324
 dosing regimens, 316*t*
 doublets vs. triplets, 228
 in induction chemotherapy, 234–243
 neoadjuvant vs. adjuvant setting, 229
 for stage IA disease, 228
 vs. carboplatin, 315
Citrus paradisi, 444
 c-KIT gene, 63*t*, 78
 Clara cells, 91, 107, 121, 124, 136
 clavicular osteosynthesis, 201
 clear cell adenocarcinoma, 127–128
Clinical Practice Guideline, 10
 clinical target volume (CTV), 262
 clinical tumor volume (CTV), 295
 clonal selection theory, 334
 cluster of differentiation 15 (CD15), 131*t*
 cobalt Gray equivalents (CGE), 278–279
 collagenase, 44
 collagens, 44–45, 68*t*
 colloid adenocarcinoma, 127, 132*t*
 combination therapy
 bevacizumab in, 315
 carboplatin in, 227–228, 319–324, 395, 406
 cisplatin in, 321–324, 395
 docetaxel in, 323, 404–405
 gefitinib in, 354–355, 377, 395, 405–406
 gemcitabine in, 235–236, 395, 404
 paclitaxel in, 227–229, 237–240, 394
 tyrosine kinase inhibitors in, 354–355
 comet assay, 41

- Commiphora mukul*, 444, 448–449
 Commit (nicotine lozenge), 12–13*t*
 comparative genomic hybridization (CGH), 65
 COMPARE algorithm, 401
 computed tomography (CT), 247–248
 cone-beam, 249
 costs of, 424
 in-room, 251–252
 computer-assisted diagnosis (CAD), 432
 conformal avoidance, 250
 connexin 26, 69*t*
 conventional fractionated radiation therapy (CFRT), 256–263
 CPT-11, 447
 Cremophor, 318
 cross-validation, 159
 Cruciferae family, 443
 cryotherapy, 117
 €-cryptoxanthin, 20, 35
 curcumin, 443, 445–446
 curcuminoids, 445–446
 Cyberknife system, 251
 cyclinD1, 75–76
 cyclin-dependent kinase 6 (CDK6), 443
 cyclin-dependent kinase inhibitor 2A, 72*t*
 cyclooxygenase 2 (COX-2), 46, 69*t*, 93, 337, 446
 cyclophosphamide, 239*t*
 cylindrical cell carcinoma, 122
 CYP1A1 gene, 36, 443
 CYP2A6 gene, 36
 CYP2A13 gene, 36
 CYP3A gene, 444
 CYP3A4 gene, 443
 CYP1B1 gene, 36
 CYP2C9 gene, 37
 CYP2D6 gene, 37
 CYP2E1 gene, 37
 cytochrome P450 enzyme modifiers, 442–444
 hypericin, 443
 indole-3-carbinol, 443
 piperine, 443
 quercetin, 444
 Z-guggulsterone, 444
 cytokeratin 7 (CK7), 131*t*
 cytokeratin 20 (CK20), 131*t*
 cytokine signalling, 73*t*
 cytopathology, 426–428
 cytosine-phospho-guanosine, 388
 cytotoxic T lymphocytes (CTL), 337–338

 daidzein, 449
 death-associated protein kinase, 69*t*
 decorin, 45
 dendritic cell vaccines, 338–339
 devil's claw root, 444
 Diagnostic and Statistical Manual of Mental Disorders (DSM), 6

 dietary patterns, 34–36
 carotenoids, 34–35
 folate, 35
 fruits and vegetables, 34
 isothiocyanates, 35
 phytoestrogens, 35–36
 diferuloylmethane, 445
 differential in gel electrophoresis (DIGE), 157
 diffuse large cell lymphoma (DLCL), 449
 dihydrofolate reductase, 324
 DIPNECH lesions, 87, 94
 diphenhydramine hydrochloride, 317
 dipping, 5
 D-Light system, 101–102
 DNA adducts, 37, 41, 63, 443
 DNA damage and repair, 38–42
 genetic polymorphisms, 38–42
 phenotypic assays, 41–42
 comet assay, 41
 DNA adducts, 41
 mutagen sensitivity, 41
 8-OGG assay, 41–42
 DNA damaging agents, 413
 DNA methylation, 66–67, 88
 DNA microarray chip, 155
 DNA polymerase, 320
 DNMT3B gene, 47
 docetaxel, 319–320. *see also*
 chemotherapeutic agents
 in combination therapy with
 bortezomib, 150*t*, 404–405
 irinotecan, 323
 dosing regimens, 316*t*
 in induction chemotherapy, 235–237, 239*t*
 vs. pemetrexed, 324
 vs. topotecan, 322
 Doll, Richard, 2
 dopamine, 6, 8, 11
 dopamine-beta-hydroxylase, 443
 Doppler ultrasonography, 198
 dose-response relationship, 21, 41, 271, 284*t*
 dose spillage, 262–263
 DOTAP:cholesterol, 76
 doubled-strand break repair (DSBR), 38
 doublets, 228, 406
 doxorubicin, 240, 285*t*, 394, 448–449
 dry snuff, 5
 DSB repair gene, 40
 dual specificity phosphatase 1, 69*t*
 Dutch-Belgian NELSON trial, 433
 dynamic spot scanning systems, 275
 dysphagia, 211, 304
 dysplasia, 85, 100–106, 111–114, 387–389

 Early Lung Cancer Action Project (ELCAP), 429–430
 Eastern Cooperative Oncology Group (ECOG), 286, 373
 EBUS-FNA, 175–176

 E-cadherin, 68*t*, 132
 EGFR gene, 77–78
 expression of, 133–135
 in molecularly targeted therapies, 63*t*
 mutations, 94
 E-guggulsterone, 444, 448–449
 Ehrlich, Paul, 334
 elastin, 45
 elderly smokers, 9
 elective nodal irradiation (ENI), 296–298
 electrocautery, 116–117
 electromagnetic guidance bronchoscopy, 432
 emphysema, 34, 191, 335
 endobronchial therapies, 114–117
 assessment of eligibility for, 114
 brachytherapy, 117
 cryotherapy, 117
 electrocautery, 116–117
 photodynamic therapy, 115–116
 endobronchial ultrasound (EBUS), 114–115, 176
 endorphins, 6
 endothelial PAS domain protein 1, 69*t*
 endothelial receptor B, 69*t*
 environmental exposures, 34
 environmental tobacco smoke (ETS), 20
 enzastaurin, 326
 epidermal growth factor (EGF), 46, 342
 epidermal growth factor receptor (EGFR), 352–362
 and bexarotene, 395
 as biomarker in adenocarcinoma, 131*t*
 biomarkers, 359
 gene amplification, 358–359
 molecular biology of, 352–353
 mutations, 94, 133–134, 357–358, 361–362
 signaling network, 353*f*
 tyrosine kinase inhibitors, 77–78, 147–149, 353–362
 epigallocatechin gallate, 443, 446–447
 epithelial cadherin, 68*t*
 epithelial-mesenchymal transition (EMT), 126, 335–336
 epoxide hydroxylase 1 (EPHX1), 38
 ErbB receptors, 191, 352–353
 ERCC1 repair gene, 39, 135
 ERCC2/XPD repair gene, 39
 ERK gene, 79
 erlotinib, 353–362. *see also*
 chemotherapeutic agents
 in combination therapy with
 bevacizumab, 377
 bexarotene, 395
 bortezomib, 405–406
 description of, 147
 molecular predictors of benefits from, 357–359
 EGFR biomarkers, 359
 EGFR gene amplification, 358–359
 EGFR mutations, 357–358

- randomized trials vs. placebo, 356–357
- resistance to, 359–362
- single-agent phase I/II clinical trials, 354–355
- esculetin, 448
- esophageal endoscopic ultrasonography (EUS), 175–176
- esophageal toxicity, 260. *see also* radiation therapy
 - clinical studies of, 304–305
 - dosimetric studies of, 305–307
- estrogen receptor, 70*t*, 161
- etoposide
 - in cisplatin-based chemotherapy, 222–228
 - in concurrent chemotherapy and radiotherapy, 288–294
 - and gemcitabine, 321
 - in induction chemotherapy, 238–240
 - in small cell lung cancer (SCLC) treatment, 329
- etretinate, 387, 389*t*
- Eucalyptus globulus*, 444
- eucalyptus oil, 444
- European Organization for Research and Treatment of Cancer (EORTC), 147, 286
- EUROSCAN study, 390–391
- EUS-FNA, 175–176
- everolimus, 327
- Exactrac Adaptive Gating system, 251
- excision repair cross-complementation group-1 (ERCC1), 131*t*, 229–230
- exhaled breath, detection of DNA abnormalities in, 436–437
- extended cervical mediastinoscopy, 172–173
- external beam radiation therapy, 423
- extracellular signal-regulated kinase (ERK), 449
- familial adenomatous polyposis (FAP), 446
- familial aggregation, 21–25
- family history, 33–34
- farnesyl transferase inhibitors, 327
- Fas ligands, 450
- FAS mRNA, 415
- FASTLINK analysis system, 27
- fenretinide, 387, 389
- ferulates, 448–449
- fetal adenocarcinoma, 123*t*, 128
- feverfew herb, 444
- FHIT gene, 76, 88
- fibronectin, 44–45
- fiducial markers, 251
- field cancerization, 89, 92
- field carcinogenesis, 387
- field defect, 92
- field effect, 89
- fine-needle aspiration (FNA), 128–129, 170*t*, 175–176, 292
- 5-methylchrysene, 63
- flavins, 100
- flavonoids, 443
- fluorescence in situ hybridization (FISH), 77, 133, 358–359, 436
- fluorodeoxyglucose, 298, 432
- fluorophores, 100
- 5-fluorouracil, 323, 372
- folate, 35
- forkhead transcription factor, 337
- fo-ti root, 444
- Fourier-transform mass spectrometry, 156
- FOXP3 transcription factor, 337
- fragile histidine triad (FHIT), 435
- fraternal twins, 7
- fruits, 34
- FUS1 gene, 63*t*, 76, 88, 416
- Gail model, 47
- gamma-aminobutyric acid, 6
- GATA-binding protein, 70*t*
- gating, 251, 261, 275
- gauze packing, 172
- G:CA:T transition, 64
- G:CT:A transversion, 64
- gefitinib, 353–362. *see also*
 - chemotherapeutic agents
 - in combination therapy, 354–355
 - description of, 147
 - molecular predictors of benefits from, 357–359
 - EGFR biomarkers, 359
 - EGFR gene amplification, 358–359
 - EGFR mutations, 357–358
 - randomized trials vs. placebo, 356–357
 - resistance to, 359–362
 - single-agent phase I/II clinical trials, 354–355
- gelatinase, 44–45
- gelatins, 44–45
- gemcitabine, 320–321
 - in combination therapy with, 235–236
 - bexarotene, 395
 - bortezomib, 150*t*, 404
 - cisplatin, 150*t*
 - in induction chemotherapy, 238, 239*t*
- gene expression profiling, 133
- general transmission probability model, 25
- gene therapy, 411–417
 - and chemotherapy, 413–415
 - clinical trials of, 413
 - and DNA damaging agents, 413
 - for metastases, 416–417
 - preclinical studies of, 412–413
 - and radiation therapy, 415–416
 - rationale for, 411–412
- genetic abnormalities, detection of, 434–435
- Genetic Epidemiology of Lung Cancer Consortium (GELCC), 27
- genetic markers, 27–28
- genistein, 442*t*, 449
- Genomic Health, 161
- genomics, 155–156
- Gibbs sampler method, 25
- ginger, 446
- gingerol, 442*t*, 446
- ginseng, 451–452
- ginsenosides, 442*t*, 451–452
- glabridin, 442*t*, 449–450
- glutamate, 6
- glutathione peroxidase I (GPX1), 38, 70*t*, 450
- glutathione-S-transferase, 327
- glutathione-S-transferase P1 (GSTP1) gene, 443
- glycine C-acetyltransferase, 70*t*
- glycyrrhetic acids, 449–450
- Gore-tex patch, 194
- G protein, 70*t*
- graft thrombosis, 211
- granulocyte-macrophage colony-stimulating factor (GM-CSF), 149, 340
- grapefruit juice, 444
- Greek Cooperative Group, 321
- green tea extract, 443, 446–447
- gremlin 1 (GREM1), 70*t*
- gross tumor volume (GTV), 262, 295
- ground glass opacities, 87, 107, 128, 129*t*
- growth factors, 46
 - insulin, 46
 - vascular endothelial, 46
- GST family, 37–38
- G-T transversion, 64
- guanine, alkylation of, 64
- guanine nucleotide binding protein, 70*t*
- guggulsterones, 442*t*, 448–449
- guggul tree, 444
- G8123 vaccine, 149
- hallmarks of cancer, 66
- Harpagophytum procumbens*, 444
- Hawaiians, susceptibility to smoking, 426
- H-cadherin, 69*t*
- health care providers, 9–10
- Helicobacter pylori*, 444
- Hemophilus influenza*, 444
- HER2 gene, 63*t*, 77–78
- HER3 gene, 77–78
- HER4 gene, 77–78
- HER2/neu, 131*t*, 443
- heterogenous nuclear ribonucleoprotein A2/B1 (hnRNP A2/B1), 436
- heterozygosity, loss of, 64–65, 435
- hexosamine, 443, 451
- hexose, 443, 451
- HIC1 gene, 70*t*
- hierarchical clustering, 158
- high dose spillage, 262–263
- high-magnification bronchoscopy, 434
- high performance liquid chromatography (HPLC), 157
- histone deacetylase enzymes, 327
- HKI-272 inhibitor, 361

- hMLH1 gene, 70*t*
homologous recombination (HR), 40
Hoosier Oncology Group, 321
Horner's syndrome, 197
host cell reactivation assay, 41
host cellular networks, 335–336
Hounsfield units (HU), 432
HRAD9 gene, 42–43
human telomerase reverse transcriptase (hTERT), 435
human telomerase RNA component (hTERC), 91
human umbilical vein endothelial cells (HUVECs), 449
hydroxyproline, 451
hypericin, 443
Hypericum, 443
Hypericum perforatum, 443
hyperlipidemia, 394–396
hypermethylation, 67
hypertriglyceridemia, 394
hypodense regions, 298
hypomethylation, 66
hypothyroidism, 394
hypoxia, 370
hypoxia-inducible factor (HIF), 370
- Icelandic Cancer Registry, 24
IDEAL trials, 354
identical twins, 7
ifosfamide, 226, 236–241
IGF binding proteins (IGFBPs), 46
IGFBP5 gene, 71*t*
IGFBP7 gene, 71*t*
image-guided radiation therapy (IGRT), 247–252. *see also* radiation therapy
 computed tomography in, 247–248
 cone-beam computed tomography, 249
 in-room computed tomography, 251–252
 markers, 251
 orthogonal kV rays, 251
 overview of, 247
 positron emission tomography in, 247–248
 respiratory gating, 251
 in stereotactic body therapy, 252
 tomotherapy, 250–255
 tumor motion, 248
immune adjuvant vaccines, 343–344
immunoeediting, 334–335
immunohistochemistry, 130–133
immunosuppression, 336
immunosurveillance, 334
immunotherapy, 337–344
 dendritic cell vaccines, 338–339
 gene delivery vaccines, 343–344
 immune adjuvant vaccines, 343–344
 modified tumor cell vaccines, 340–341
 peptide vaccines, 341–343
 protein vaccines, 341–343
- indole-3-carbinol, 443
induction chemotherapy, 233–243
 expected outcome for, 234*t*
 meta-analyses of, 241–242
 phase II trials, 234–238
 early-stage disease, 236–238
 second-generation regimens, 234
 stage III disease, 234–238
 third-generation regimens, 235–236
 before radiotherapy, 284–286
 randomized trials, 239–241
 early-stage disease, 240–241
 stage III trials, 238–240
 surgical morbidity/mortality in, 242–243
inflammation, 92–93
 anti-inflammatory genes, 45
 proinflammatory genes, 45–46
 and radiation therapy, 303–304
in-room computed tomography, 251–252
insulin growth factor binding protein, 70–71*t*
insulin growth factors (IGFs), 46
INTACT trials, 356
intensity-modulated proton therapy (IMPT), 275, 277, 301–302
intensity-modulated radiation therapy (IMRT), 272, 301
intercellular adhesion molecule-1 (ICAM-1), 449
interferon regulatory factor 7, 71*t*
interleukin-8, 449
interleukin 1 beta (IL1B), 45–46
interleukin 6 receptor, 71*t*
intermediate dose spillage, 262–263
internal gross target volume (IGTV), 278
internal target motion, 248
International Adjuvant Lung Cancer Trial, 225
International Agency for Research on Cancer (IARC), 33
International Early Lung Cancer Action Project (I-ELCAP), 426, 429–431
intraepithelial neoplasia (IEN), 111–112
 longitudinal outcome of, 112*t*
 natural history of, 112–113
intron, 40
invasive adenocarcinoma, 125–127
 cytology of, 129
 molecular correlates of, 130–131
invasive cancer, 104*f*
Iressa, 147, 354
irinotecan, 322–323, 379, 450
irinotecan biliary index, 450
iroquois homeobox protein 4, 71*t*
isobologram, 284
isoflavones, 449
isoliquritigenin, 447
isothiocyanates, 35
isotretinoin, 390–391
- jagzike sheep retrovirus (JSRV), 136
Japan Clinical Oncology Group, 237
- Japanese-Americans, susceptibility to smoking, 426
Japanese Oncology Group Trial 9304, 223–224
John Hopkins Early Lung Cancer Detection Project, 103–104, 427
junk DNA, 66
- kaempferol, 443
Kaplan-Meier survival curves, 158
Karl Storz Endoscopy, 101
kava-kava root, 444
keratin 8, 71*t*
kinase multitargeting, 361
Ki-ras mutation, 136
Knudson, Alfred, 61
Koop, C. Everett, 1
K-ras mutations, 341
KRAS oncogenic mouse model, 91–92
kV imaging system, 251
- LACE pooled analysis, 227–228
lactones, 451–452
laminin, 45
large cell carcinoma (LCC), 62
Latinos, susceptibility to smoking, 426
lead time bias, 424–425
left atrium, invasion of, 213
left carinal pneumonectomy, 206–208
Leksell, Lars, 258
lesions, 84–95
 early detection of, 422, 431–433
 precursor, 84–95
 preneoplastic, 84–95
 sizes of, 422
lethal-potentially lethal (LPL) model, 259
leucovorin, 323
leukoplakia, 387
LIFE-Lung system, 100–103
LIG4 repair gene, 40
limited resection, 188–191
linear energy transfer (LET) radiation, 272–273
linear quadratic (LQ) formula, 259
linkage analysis, 8, 27–28
lipofuscin, 100
lipoma HMGIC fusion partner, 71*t*
lipopigments, 100
lipopolysaccharides, 450
lipxygenases, 447
Liquiritia glabra, 447
LKB1 gene, 91
lobectomy, 180–191, 423
LODLINK, 28
loss of heterozygosity (LOH), 20, 64–65, 435
luciferase assays, 47
lung cancer, 1–3
 and biobehavioral model of nicotine addiction, 10*f*
 deaths from, 1–3, 421
 demographics of, 421–422

- early detection of, 65–66, 422
- epigenetic basis of, 66–67
- etiology of, 62–63
- extended resections for, 194–216
- familial aggregation of, 21–25
- incidence of, 62
- linkage analysis of, 27–28
- minimally invasive surgery for, 180–191
- molecular genetics of, 63–65
- molecular pathogenesis of, 87–88
- new cases of, 33, 421
- preneoplastic lesions of, 84–95
- radiation dose for, 271
- risk assessment, 36–48
- risk factors, 33–36
- screening program, 421–437
 - and second-hand smoke, 3
 - and smoking, 1–3
 - susceptibility genes, 20–29
 - susceptibility to, 33
 - targeted genetic therapy for, 411–417
- treatment of, 62–63
- lung cancer patients
 - families of, 21–25
 - screening program for, 425–426
 - smoking among, 3–4
 - statistics, 271
- lung scar cancer, 126
- Lung Screening Study (LSS), 430–431
- lung toxicity, 300–304. *see also* radiation therapy
 - and improved radiation delivery, 301–303
 - and inflammatory responses, 303–304
 - and predictors inflammatory responses, 304
 - reduction of, 301–304
- lutein, 35
- lycopene, 448
- lymph nodes, 114–115
 - assessment of, 114–115
 - detection of metastatic disease in, 169
 - irradiation of, 295–297
 - mediastinal, 170–176
 - sampling of, 183–184
- lysyl oxidase, 71*t*
- Madagascar periwinkle, 323
- magnetic resonance imaging (MRI), 198
- major histocompatibility complex (MHC), 335, 337–338
- malondialdehyde, 448–449
- Marchesani classification, 122
- marimastat, 327
- markers, 251
- Marlex mesh, 195
- mass spectrometry (MS), 156
- matrilysin, 45
- matrix-assisted laser desorption/ionization (MALDI), 156–157, 160
- matrix metalloproteinases (MMPs), 44–45, 326–327
 - matrix metalloproteins (MMPs), 44–45
 - MAX dimerization protein, 71*t*
 - maximal intensity projection (MIP), 278
 - maximum tolerated dose (MTD), 264
 - Mayo Clinic, 427
 - Mayo Lung Project, 427
 - MBD1 gene, 47
 - MDM2 gene, 42
 - mean lung dose (MLD), 248
 - Medawar, Peter, 334
 - median sternotomy, 172
 - mediastinoscopy, 169–176
 - alternative methods to, 175–176
 - anterior, 172–173
 - complications, 171–172
 - extended cervical, 172–173
 - future recommendations, 176–177
 - history of, 170
 - indications for, 170–171
 - mortality rates of, 171–172
 - procedure, 171
 - redo, 174–175
 - results, 171
 - video-assisted, 173
 - mediastinum, radiographic staging of, 169–170
 - megavoltage beam, 248, 249
 - MEK gene, 63*t*, 79
 - melanoma-associated antigen (MAGE), 342–343
 - Memorial Sloan-Kettering Cancer Center, 427
 - Mendelian codominant inheritance, 25–26
 - Mentha piperita*, 444
 - mesothelioma, 132
 - messenger RNA, 155
 - meta-analysis, 241–242
 - metabolic boosts, 298
 - metachronous lesions, 105
 - metalloelastases, 45
 - metaplasia, 104*f*, 106, 389–390
 - metaplasia index (MI), 389
 - meth, 35
 - methylation, 35, 67, 89*f*, 388
 - methylation-related genes, 46–47, 75–76, 88
 - 5-methylchrysene, 63
 - microarray chip, 155
 - microsatellites, 65–66, 435
 - microtubules, 317, 319
 - minimally invasive surgery, 180–191
 - benefits of, 183
 - adequacy of nodal clearance, 183–184
 - decreased pain, 184–185
 - earlier discharge, 187
 - equivalent long-term survival, 187–188
 - lower morbidity, 185–187
 - contraindications to, 182–183
 - future directions, 191
 - limited resection in, 188–191
 - technique of, 180–182
 - miscoding mutation, 64
 - mismatch repair (MMR), 38, 70*t*
 - mitomycin, 224, 226, 228, 234–241
 - mixed subtype adenocarcinoma, 123*t*, 125–127
 - MMP1 collagenase, 44
 - MMP2 gelatinase, 44
 - MMP9 gelatinase, 45
 - MMP7 matrilysin, 45
 - MMP12 metalloelastase, 45
 - MMP3 stromelysin, 45
 - MMR repair gene, 40–41
 - MNS16A minisatellite, 44
 - modified tumor cell vaccines, 337–344
 - molecular genetics, of lung cancer
 - aneuploidy, 64–65
 - chromosomal instability, 64–65
 - DNA methylation, 66–67
 - loss of heterozygosity, 64–65
 - oncogenes, 76–77
 - preneoplasia, 65–66
 - receptor tyrosine kinases, 77–79
 - tobacco smoke, 63–64
 - tumor suppressor genes, 67–76
 - molecular pathogenesis, 87–88
 - molecular profiling, 153–165
 - clinical applications, 160–164
 - early detection and diagnosis, 160
 - selection of therapy, 163–164
 - subclassification/staging, 161–162
 - data analysis and statistics, 158–160
 - future directions, 164–165
 - overview of, 153–154
 - techniques in, 153–158
 - genomics, 155–156
 - proteomics, 156–158
- molecular-targeted therapies, 63*t*
- monoamine oxidase (MAO) inhibitor, 15, 443
- monoclonal antibodies, 361–362
 - anti-idiotypic, 343–344
 - in molecular profiling, 158
 - and VEGF signaling, 371*f*
- monoclonal antibody-based protein assays, 158–159
- motion control devices, 261–262
- MTHFR gene, 47
- mTOR gene, 63*t*, 327
- mucinous adenocarcinoma, 123*t*, 125–127, 132*t*
- mucinous cystadenocarcinoma, 127
- MUC-1 peptides, 339
- multitargeted antifolate, 324–325
- mutagen sensitivity, 41
- mutations, 64, 357–358
 - miscoding, 64
- myeloperoxidase (MPO), 37
- myelosuppression, 317–320, 322–324
- myogenic differentiation 1, 72*t*
- myo-inositol, 448

- N-acetylcysteine, 322–324, 390–391
 N-acetyltransferases (NATs), 38–39
 NAD(P)H:quinone oxidoreductase 1 (NQO1), 38
 naringenin, 443
 nasal spray, 11–14
 National Cancer Institute, 391, 427
 National Cancer Institute of Canada Clinical Trials Group JBR.10, 226
 National Lung Cancer Screening Trial (NLST), 426, 433
 NBS1 repair gene, 40
Neisseria meningitidis, 342
 NELSON trial, 433
 neoadjuvant chemotherapy, 229
 antiangiogenic agents in, 377–378
 with chemotherapy, 305
 for N2 disease, 174–175
 with radiation therapy, 293–294
 in stage III nonsmall cell lung cancer (NSCLC), 236
 three-drug regimen in, 236
 vs. adjuvant chemotherapy, 229
 Neovastat, 327, 378
 NER repair gene, 41–42
 neuroendocrine tumor, precursor lesions, 87
 neuronal cell adhesion molecule, 72*t*
 neurotransmitters, 6
 N-(4-hydroxyphenyl) retinamide, 447
 nickel, 34
 Nicoderm, 12–13*t*
 Nicorette, 12–13*t*
 nicotinamide adenine dinucleotide (NADH), 100
 nicotine addiction, 6–7, 10*f*
 nicotine-derived nitrosamine ketone (NKK), 443, 450
 nicotine gums, 11–14
 nicotine lozenge, 11–14
 nicotine nasal spray, 11–14
 nicotine patches, 11–14
 nicotine replacement therapy, 11–15
 nicotinic acetylcholine receptors, 15
 Nicotrol, 12–13*t*
 nitrosamines, 136
 nitrous oxide, 117
 N-nitrosamines, 64
 N-nitrosodiethylamine (NDEA), 36
 N'-nitrosodimethylamine (NNN), 36
 nodal irradiation, 296–298
 nodal sampling, 183–184
 nonhomologous end-joining (NHEJ) pathway, 40
 nonsmall cell lung cancer (NSCLC), 62
 induction chemotherapy for, 233–243
 percentage of total lung cancer cases, 271
 radiation therapy/chemotherapy for, 283–307
 concurrent, 286
 concurrent combination chemotherapy, 286–288
 concurrent followed by resection, 292–294
 concurrent single-agent chemotherapy, 286
 induction chemotherapy before radiotherapy, 284–286
 rationale for, 283–284
 sequential vs. concurrent, 288–292
 staging of, 169–176
 synchronous lesions in, 105
 treatment of, 144–150, 266–267
 antiangiogenic agents, 370–379
 biological agents, 325–327
 chemotherapeutic agents, 315–324
 medically inoperable stage I patients, 263–266
 operable, 266–267
 proteasome inhibitors, 400–407
 nonsmokers, risk of lung cancer for, 21
 non-smoking related pathways, 94
 norepinephrine, 6, 15
 North American Intergroup Trial INT0115, 222–223
 North Central Cancer Treatment Group (NCCTG), 237
 Notch3 gene, 131*t*
 Novadaq Inc., 100
 nuclear factor kappa B (NF-κB), 93, 445, 449–450
 nucleotide incision repair (NER), 38, 64
 nutrition and dietary patterns, 34–36
 carotenoids, 34–35
 folate, 35
 fruits and vegetables, 34
 isothiocyanates, 35
 phytoestrogens, 35–36
 occupational exposures, 34
 orophagia, 304
 8-OGG assay, 41–42
 OGG1 repair gene, 39–40
 oleoresin, 448
 oligonucleotide microarrays, 133
 Olympus bronchovideoscope, 101
 Olympus Corp., 101
 oncogenes, 26, 61, 76–77
 Onco-LIFE system, 101
 Oncotype DX assay, 161
 online databases, 159
 open lobectomy, 180–182
 optical coherence tomography (OCT), 99
 oral inhaler, 11–14
 organ motion, 248
 orthogonal kV rays, 251
 OSI-774, 354
 overdiagnosis bias, 424–425
 ovine pulmonary adenocarcinoma (IPA), 136
 oxyresveratrol, 443
 Pacific yew tree, 317
 paclitaxel, 317–318
 in chemotherapy, 146–147
 clinical trials, 146*t*
 in combination therapy with bexarotene, 394
 carboplatin, 227–228, 237–238
 cisplatin, 227–229, 240
 paclitaxel poliglumex, 318–319
 Panax ginseng, 451–452
 Pancoast-Tobias syndrome, 194, 197–202
 papillary adenocarcinoma, 123*t*, 127
 parenchyma, 181, 189, 202, 204, 447
 p14ARF tumor suppression gene, 412
 passive scattering systems, 274–275
 passive smoking, 20
 pemetrexed, 324–325
 Pentax Corp., 101
 Pentax SAFE-3000 system, 101
 p450 enzyme inducers, 318
 peppermint oil, 444
 peptide vaccines, 341–343
 peripheral adenocarcinoma, 135–136
 peripheral airway, 121–122
 p16 gene, 67
 p53 gene, 42
 gene replacement, 412–413
 in molecularly targeted therapies, 63*t*, 413
 mutations, 393, 435
 in proteasome inhibition, 401–402
 as tissue biomarkers, 131*t*
 tumor suppression, 411–412
 tumor-suppressor pathway, 67, 75
 p73 gene, 42, 72*t*
 P-glycoprotein, 443
 P-glycoprotein substrates, 394
 phenotypic assays, 41, 43
 phenylalanine, 100
 photodynamic therapy, 115–116, 423
 photons, 272
 photon therapy, 275–276
 Physicians' Health Study, 389
 phytic acid, 448
 phytoalexins, 442–443
 phytoestrogens, 35–36, 447, 449
 piperine, 442*t*, 443
Piper longum, 443
Piper methysticum, 444
Piper nigrum, 443
 pipe tobacco, 5
 P13K gene, 63*t*
 placebo, 356–357
 placental growth factor, 72*t*
 planning target volume (PTV), 295
 planning treatment volume (PTV), 261
 plasminogen receptor, 73*t*
 platelet-derived endothelial growth factor (PDGF), 369

- platinum-refractory patients, 320
 Pleckstrin homology-like domain, 72*t*
 pleiomorphic adenoma gene-like 1, 72*t*
 pleural symphysis, resections
 pneumonectomy, 113, 203–210, 293
 polycyclic aromatic compounds, 34
 polycyclic aromatic hydrocarbon (PAH),
 36, 136
Polygonum multiflorum, 444
 polymorphisms, 28–29
 porphyrins, 100
 PORT Meta-Analysis Trialists Group, 221
 positron emission tomography (PET),
 247–248
 in lung cancer screening, 432
 in lymph node assessment, 114–115
 in nodal treatment planning, 298
 postoperative radiation therapy (PORT),
 221
 postthoracotomy pain, 184
 p27 protein, 401
 preclinical phase, 422
 prednisolone, 304
 prednisone, 304
 pregnancy category C agents, 15
 pregnancy category D agents, 14
 pregnane X receptor (PXR), 444
 preneoplasia, 65–66
 preneoplastic lesions, 84–95
 adenocarcinoma precursor lesions,
 86–87
 detection of, 99–106
 in central airways, 99–107
 in peripheral lung, 106–107
 neuroendocrine tumor precursor
 lesions, 87
 pathology of, 85
 squamous cell carcinoma, 85–86
 treatment of, 111–118
 proangiogenic molecules, 369
 proapoptotic genes, 412
 proinflammatory genes, 45–46
 promoter hypermethylation, 66–67,
 75–76, 435–436
 prostaglandin E2 (PGE2), 337
 proteasome inhibition therapy, 400–407
 with chemotherapy, 404–406
 single-agent trials, 403–404
 proteasome inhibitor, 149
 protein kinase C, 326, 443
 protein vaccines, 341–343
 proteomics, 156–158
 proteosome, 326
 protocadherin, 72*t*
 proton beams, 273–274
 proton therapy, 271–280
 biologic effectiveness of, 272
 clinical trials, 278–279
 intensity-modulated, 275
 overview of, 271–272
 proton beams, 273–274
 proton delivery, 274–277
 dynamic spot scanning systems, 275
 image-guided, 276–277
 passive scattering systems, 274–275
 rationale for, 272–273
 reduced normal tissue dose with,
 277
 tumor motion, 278
 vs. photon therapy, 275–276
 pulmonary adenocarcinoma, 122–124
 pulmonary angiography, 203
 pulmonary diseases, 2*t*, 335
 pulmonary fibrosis, 335
 pulmonary trunk, invasion of, 213
 quercetin, 444
 quinazolinamines, 147
 racial differences, in susceptibility to
 smoking, 426
 RAD001, 327
 radiation pneumonitis, 264
 radiation sensitization, 283
 radiation therapy, 294–307
 with chemotherapy, 283–294
 concurrent, 286–288
 concurrent followed by resection,
 292–294
 induction chemotherapy before
 radiotherapy, 284–286
 sequential vs. concurrent, 288–292
 conformal, three-dimensional, 295–296
 elective nodal irradiation, 296–298
 and gene replacement, 415–416
 intensity-modulated, 272, 301
 portal configurations, 294
 toxicity of, 299–307
 esophageal toxicity, 304–307
 lung toxicity, 300–304
 treatment volumes, 294
 two-dimensional, 294–295
 Radiation Therapy Oncology Group
 (RTOG), 260–261, 271, 285–288
 radiofrequency ablation (RFA), 423
 radiographic screening, 422
 radiotherapy. *see* radiation therapy
 radon, 34
 RAF gene, 79
 Raf kinase, 326
 randomized control trials (RCT), 426
 rapamycin, 327
 Ras association, 73*t*
Rasayanas, 451
 RAS gene, 63*t*, 78
 Ras-induced senescence, 73*t*
 Ras oncogene, 327
 RASSF1A gene, 67, 76, 88
 RB pathway, 75–76
 receptor tyrosine kinases, 77–79. *see also*
 epidermal growth factor receptor
 (EGFR)
 c-KIT gene, 78
 EGFR gene, 77–78
 ERK gene, 79
 inhibitors, 370–371
 MEK gene, 79
 RAF gene, 79
 RAS gene, 78
 recombinant vaccinia vector, 344
 red clover blossom, 444
 red ginseng, 451–452
 redo mediastinoscopy, 174–175
 refractory cutaneous T cell lymphoma,
 393–394
 relative biologic effectiveness (RBE),
 272
 reproductive effects, of smoking, 2*t*
 resections, 194–216
 anastomotic technique, 208–209
 aorta invasion, 213
 approaches to, 204
 carinal, 202–208
 chest wall invasion in, 194–197
 complications, 215
 and concurrent chemotherapy/radiation
 therapy, 292–294
 contraindications, 203–204
 effects of SVC clamping, 211–212
 indications, 203–204
 left atrium invasion, 213
 limited, 188–191
 main pulmonary trunk invasion, 213
 postoperative care, 209–210
 preoperative evaluation, 213–214
 release maneuvers, 208
 in superior sulcus tumors, 197–202
 surgical technique of, 204
 SVC invasion, 210–211
 vascular indications, 211
 vertebral body invasion, 216
 respiratory diseases, prior history of, 34
 respiratory gating, 251
 respiratory motion, 248
 resveratrol, 442–443
 retinoblastoma, 22, 61, 411
 retinoic acid receptors (RARs), 72*t*, 76,
 386–388, 391–392
 retinoids, 386–392
 in lung cancer treatment, 326, 387–388
 molecular biology of, 386–387
 in primary chemoprevention, 388–389
 in secondary chemoprevention,
 389–390
 in tertiary chemoprevention, 390–391
 retinoid X receptors (RXRs), 386–388,
 391–392
 retinol, 35, 389
 retinyl palmitate, 390–391
 reverse transcriptase, 90, 415, 443
 rexinoids, 392–396
 ribonuclease T2, 73*t*
 ribonucleotide reductase, 131*t*, 230
 ribonucleotides, 131*t*
 right carinal pneumonectomy, 205–206
 risk alleles, 28–29

- risk factors, 21
 apoptosis, 43–44
 assessment models, 47–48
 carcinogen metabolism, 36–38
 cell cycle control, 42–43
 DNA damage and repair, 38–42
 comet assay, 41
 DNA adducts, 41
 genetic polymorphisms, 38–42
 mutagen sensitivity, 41
 8-OGG assay, 41–42
 phenotypic assays, 41
 environmental/occupational exposures, 34
 epidemiologic, 33–34
 family history, 33–34
 prior respiratory diseases, 34
 smoking, 33
 genetic variations, 36
 growth factors, 46
 methylation-related genes, 46–47
 nutrition/dietary patterns, 34–36
 carotenoids, 34–35
 folate, 35
 fruits and vegetables, 34
 isothiocyanates, 35
 phytoestrogens, 35–36
 telomerase, 44
 telomere, 44
 tumor microenvironment, 44–46
 ROBO1 gene, 88
 Royal Brompton Hospital, 240
 runt-related transcription factor, 73*t*
- safety, of screening program, 423–424
scapula alata, 201
 scar carcinoma, 126
 Sclerosing hemangioma, 128
 screening programs, 421–437
 with chest computed tomography, 428–433
 with chest radiography, 426–428
 detection of DNA abnormalities in, 434–437
 blood, 435–436
 bronchoscopic samples, 436
 exhaled breath, 436–437
 sputum, 436
 direct visualization of abnormal tissue in, 433–434
 effectiveness of, 426
 pitfalls in, 424–425
 lead time bias, 424–425
 overdiagnosis bias, 424–425
 prerequisites for, 421–424
 acceptability, 422–423
 defined preclinical phase, 422
 low cost, 424
 potential for cure, 422
 safety, 423–424
 target population, 425–426
- secondary primary tumors, 390–391
 second-hand smoke, 3
 secreted frizzled-related protein, 73*t*
 segmentectomy, 113, 189, 423
 segregation analyses, 25–26
 selenazolidine-4(2-oxo)-carboxylic acid, 450
 selenium, 450
 selenocystine, 450
 selenomethionine, 450
 selenoproteins, 450
 semaphorin 3B gene, 76, 88
 serine/threonine protein kinase (STK), 69*t*, 79, 91, 327
 serotonin, 6
 short tandem repeat polymorphism (STRP), 27, 90–92
 sialic acid, 443, 451
 Sibson's fascia, 200
 sigmet ring adenocarcinoma, 123*t*, 127
 SIMWALK2, 27
 single-nucleotide polymorphisms (SNPs), 36, 156
 single photon emission computed tomography (SPECT), 295
 Smad genes, 343
 small cell lung cancer (SCLC), 62. *see also*
 lung cancer; nonsmall cell lung cancer (NSCLC)
 histopathological changes in, 86*f*
 pathogenesis of, 92
 treatment of
 antiangiogenic, 379–380
 bortezomib, 406–407
 smoked tobacco, 4–5
 smokeless tobacco, 4
 smokers, 4–5
 demographics of, 4*t*
 nicotine addiction in, 6–7
 relatives of, 21–25
 risk of lung cancer for, 2–3
 smoking, 1–4
 and carotenoids, 391–392
 economic costs of, 1
 genetics of, 7–8
 health consequences of, 2*t*
 initiation to, 5–6
 risk factor for lung cancer, 33
 smoking cessation, 1–16
 benefits of, 8–9
 interventions, 10
 behavioral counseling, 10
 guidelines, 11*t*
 health care providers, 9–10
 and lung cancer, 1
 overview of, 1
 pharmaceutical aids in, 11–15
 nicotine replacement therapy, 11–15
 sustained-release bupropion, 15
 varenicline tartrate, 15
 snuff, 5
- solid adenocarcinoma, 123*t*
 sorafenib, 63*t*, 79, 326, 372*t*, 374–377
 Southwest Oncology Group trial, 146, 241, 354, 379
 soy-based diet, 449
 spit tobacco, 5
 spread-out Bragg peak (SOBP), 273–274
 sputum, 88, 427–430, 436
 sputum atypia, 88, 103–105, 389
 squalamine, 380
 squamous cell carcinoma, 85–86
 chemoprevention for, 390
 histopathological changes in, 86*f*
 pathogenesis of, 89–90
 preclinical phase, 422
 radiotherapy for, 284
 squamous dysplasia, 389–390
 squamous metaplasia, 390
 SRC gene, 63*t*
 Src kinase, 327
 SRY-box 15 gene, 73*t*
 St. John's wort, 443
 stage I patients, 263–267
 medically inoperable, 263–266
 operable, 266–267
 predictive models, 162
 survival rates for, 221
 standard uptake value (SUV), 298
 statistical models, 47–48
 STELLAR trials, 318–319
 stereotactic body radiotherapy (SBRT), 256–267
 and cone-beam computed tomography, 249
 dosimetry of, 262–263
 esophageal toxicity in, 260
 guidelines for, 260–261
 history of, 257–259
 image-guided, 252
 immobilization in, 261–262
 lung toxicity in, 260
 overview of, 256–257
 physics of, 262–263
 radiobiology of, 259–260
 normal tissue biology and tolerance, 259–260
 tumor biology, 259
 target motion in, 261–262
 treatment of stage I patients, 263–267
 medically inoperable, 263–266
 operable, 266–267
 stereotactic radiosurgery (SRS), 258
 STK15 gene, 43
 stratifin, 68*t*
 stroke, risk for, 9
 stromelysin, 45
 suberoylanilide hydroxamic acid (SAHA), 327
 sugar tumor, 127–128
 sulfotransferase (SULT), 38
 sunitinib, 376
 superior sulcus tumors, 197–202

- superior vena cava (SVC), 197
 - clampage of, 211–212
 - invasion of, 210–211
- supervised statistical techniques, 158
- suppressor of variegation 3-9 homolog 2 (SUV39H2), 47
- surface enhanced laser
 - desorption/ionization (SELDI), 156–157, 160
- Surgeon General, 1
- surveillance epidemiology and end results (SEER), 99
- survival rates, 422
 - in cardiopulmonary bypass, 215
 - in chemotherapy, 321–324, 395
 - in complete resections, 196*t*
 - in 3D conformational radiotherapy, 296
 - in limited resections, 189
 - in treatment of superior sulcus tumors, 202
- susceptibility to lung cancer, 20–29
 - biological risk factors, 21
 - dose-response relationship, 21
 - familial aggregation in, 21–25
 - linkage analysis, 27–28
 - oncogenes, 26
 - polymorphisms, 28–29
 - segregation analyses, 25–26
 - and tobacco smoke inhalation, 21
 - tumor suppressor genes, 26
- sustained-release bupropion, 15
- SUV39H2 gene, 47
- SVC syndrome, 210–211
- Swedish Family Cancer, 21–25
- synchronous lesions, 105, 114
- Synchrony option, 251

- Taiwan, lung cancer patients in, 25
- TALENT trials, 356
- Tanacetum parthenium*, 444
- tandem mass spectrometry, 156–157
- tanomastat, 327
- Tarceva, 147, 354
- targeted genetic therapy, 411–417
 - and chemotherapy, 413–415
 - and DNA damaging agents, 413
 - for metastases, 416–417
 - p53 gene replacement in, 412–413
 - and radiation therapy, 415–416
 - rationale for, 411–412
- target population, in lung cancer
 - screening, 425–426
- taxanes, 317–330
 - docetaxel, 319–320
 - paclitaxel, 317–318
 - paclitaxel poliglumex, 318–319
 - recommendations, 320
- Taxus brevifolia*, 317, 319
- T-box 1 gene, 73*t*
- T1 class, 422
- T2 class, 422
- Telcyta, 327

- telomerase, 44, 63*t*, 443
- telomerase reverse transcriptase (hTERT), 91
- telomeres, 44
- temburni* leaf, 5
- temsirolimus, 327
- tendu* leaf, 5
- Terminalia arjuna*, 450
- thalidomide, 379
- The Cancer Genome Atlas (TCGA), 63
- thoracoscopic lobectomy, 180–191
 - benefits of, 183
 - adequacy of nodal clearance, 183–184
 - decreased pain, 184–185
 - earlier discharge, 187
 - equivalent long-term survival, 187–188
 - lower morbidity, 185–187
 - contraindications to, 182–183
 - future directions, 191
 - limited resection in, 188–191
 - technique of, 180–182
 - vs. open lobectomy, 180–182
- 3D conformal radiotherapy (3DCRT), 273, 277, 295–296
- 3p tumor suppressor genes, 76
- threonine kinases, 326
- thyroid transcription factor, 131*t*
- tight junction protein, 73*t*
- time-of-flight mass spectrometry, 156
- TIMP metalloproteinase inhibitor 3, 73*t*
- Tinospora cordifolia*, 444
- tissue factor pathway inhibitor, 73*t*
- T3 lesions, 195–196
- TLK286 glutathione analogue, 327
- T lymphocytes, 335
- T790M mutation, 361
- tobacco, 4–5
 - smoked, 4–5
 - smokeless, 5
- tobacco smoke, 2
 - inhalation of, 21
 - and lung cancer, 63–64
 - second-hand, 3, 20–21
- tobacco use, 6–7
 - factors in, 5–7
 - nicotine addiction, 6–7
 - smoking initiation, 5
 - genetics of, 7–8
 - and public health, 1
- tomotherapy, 250–255
- topoisomerase inhibitors, 321–323
 - irinotecan, 322–323, 379, 450
 - topotecan, 322, 407
- topotecan, 322, 407
- transdermal nicotine patches, 11–14
- transesophageal echography, 203
- transforming growth factor-beta (TGF-beta), 343
- transmembrane protein, 73*t*
- transplantation, 145–146
- trans-3,4',5'-trihydroxystilbene, 442–443

- treatment-related pneumonitis (TRP), 301–302
- T regulatory cells, 336
- TRIBUTE trials, 356
- Trifolium pratense*, 444
- triplets, 228
- tryptophan, 100
- tube thoracostomy, 432
- tumor angiogenesis, 369
 - inhibition of, 370
 - in lung cancer, 369
 - regulators of, 369–370
- tumor-associated antibodies, 435
- tumor-associated glycoprotein 72 (TAG72), 131*t*
- tumor biology, 259
- tumorigenesis, 335–336
- tumor infiltrating lymphocytes (TIL), 126, 336
- tumor microenvironment, 44–46
 - inflammation, 45–46
 - microenvironmental factors, 44–46
- tumor motion, 278
- tumor necrosis factor, 338, 449–450
 - receptors, 69*t*
- tumor node metastasis (TNM), 194
- tumors, sizes of, 422
- tumor suppressor genes, 62, 67–76
 - inactivation of, 66–67
 - oncogenes and, 26
 - 3p, 76
 - p53 pathway, 67, 75
 - RB pathway, 75–76
- TUNEL method, 44
- twins, 7
- twist homolog, 73*t*
- two-dimensional radiotherapy, 294–295
- two-hit hypothesis, 61
- tyrosine, 100
- tyrosine kinase inhibitors, 147–149
 - in combination therapy, 354–355
 - molecular predictors of benefits from, 357–359
 - EGFR biomarkers, 359
 - EGFR gene amplification, 358–359
 - EGFR mutations, 357–358
 - randomized trials vs. placebo, 356–357
 - resistance to, 359–362
 - single-agent phase I/II clinical trials, 354–355
- tyrosine kinase receptors, 77–79
 - c-KIT gene, 78
 - EGFR gene, 77–78
 - ERK gene, 79
 - MEK gene, 79
 - RAF gene, 79
 - RAS gene, 78
- tyrosine kinases, activation of, 90

- unsupervised clustering, 158–159
- unsupervised statistical techniques, 158–159

- urethane, 136
- uronic acid, 451
- U.S. Public Health Service, 1–3
- Utah Population Database, 23
- vaccines, 337–344
 - dendritic cell vaccines, 338–339
 - gene delivery vaccines, 343–344
 - immune adjuvant vaccines, 343–344
 - modified tumor cell vaccines, 340–341
 - peptide vaccines, 341–343
 - protein vaccines, 341–343
- varenicline, 12–15
- vascular endothelial growth factor (VEGF), 46, 90, 369–370, 378
- vatalanib, 376
- VATS lobectomy, 180–191
 - benefits of, 183
 - adequacy of nodal clearance, 183–184
 - decreased pain, 184–185
 - earlier discharge, 187
 - equivalent long-term survival, 187–188
 - lower morbidity, 185–187
 - contraindications to, 182–183
 - future directions, 191
 - limited resection in, 188–191
 - technique of, 180–182
 - vs. mediastinoscopy, 176
- vegetables, 34
- VEGF gene, 63*t*
- VEGF receptors, 90
- VEGF Trap, 375
- vertebral body, invasion of, 216
- video-assisted mediastinoscopy, 174–175
- video-assisted thoracic surgery lobectomy. *see* VATS lobectomy
- vinblastine, 323
 - clinical trials, 225
 - in concurrent chemotherapy and radiotherapy, 288–289
 - for early-stage cancer treatment, 240–241
 - in induction chemotherapy before radiotherapy, 285
 - in platin-based adjuvant chemotherapy, 222–226
 - in second-generation regimens, 234
 - in treatment of microscopic/nodal disease, 298
- vinca alkaloids, 228, 323–324
- vincristine, 323, 394
- vindesine, 323
 - clinical trials, 221–228
 - in induction chemotherapy, 239*t*
 - in second-generation regimens, 234
 - in third-generation regimens, 236
- vinorelbine, 323–324
 - clinical trials, 221–228
 - dosing regimens, 316*t*
- vinyl carbamate, 393
- vinyl chloride, 34
- virtual bronchoscopy, 433
- vitamin A deprivation, and cancer, 386
- vitamin A supplements, 20
- volatile organic compounds (VOCs), 436–437
- wedge resection, 145, 189–191, 423
- Weinstein, Bernard, 62
- Wellbutrin, 15
- whitanolide D, 451
- whitanolides, 451
- white-light bronchoscopy, 99–102, 434
- Wilm's tumor, 131*t*, 342
- Withania somnifera*, 451
- withdrawal symptoms, 6
- WT1 gene, 342
- XPA repair gene, 39
- XPC repair gene, 39
- XPG repair gene, 39
- X-rays, 272–276
- XRCC1 repair gene, 40
- XRCC3 repair gene, 40
- ZD1839, 354
- ZD6474 inhibitor, 362, 374–376
- zeaxanthin, 35
- zerumbone, 446
- Z-guggulsterone, 444, 448–449
- zinc finger E-box binding homeobox 1 (zeb1), 131*t*
- zinc finger protein, 73*t*
- Zingiber officinale*, 446
- Zingiber zerumbet*, 446
- Zyban, 15